Show simple item record

dc.contributor.authorMoermond, CTA
dc.contributor.authorPuhlmann, N
dc.contributor.authorBrown, AR
dc.contributor.authorOwen, SF
dc.contributor.authorRyan, J
dc.contributor.authorSnape, J
dc.contributor.authorVenhuis, BJ
dc.contributor.authorKümmerer, K
dc.date.accessioned2023-02-08T10:19:12Z
dc.date.issued2022-08-23
dc.date.updated2023-02-07T20:08:11Z
dc.description.abstractMedicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.en_GB
dc.description.sponsorshipInnovative Medicines Initiative 2 Joint Undertakingen_GB
dc.format.extent699-705
dc.identifier.citationVol. 9, No. 9, pp. 699-705en_GB
dc.identifier.doihttps://doi.org/10.1021/acs.estlett.2c00446
dc.identifier.grantnumber875508en_GB
dc.identifier.urihttp://hdl.handle.net/10871/132438
dc.identifierORCID: 0000-0002-3892-8993 (Brown, A Ross)
dc.language.isoenen_GB
dc.publisherAmerican Chemical Societyen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/36118957en_GB
dc.rights© 2022 American Chemical Society. Open access under a CC BY-NC-ND 4.0 licenceen_GB
dc.subjectpharmaceuticalsen_GB
dc.subjectdrug discovery and developmenten_GB
dc.subjectenvironmenten_GB
dc.subjectsustainabilityen_GB
dc.subjectcriteriaen_GB
dc.subjectwater qualityen_GB
dc.titleGREENER pharmaceuticals for more sustainable healthcareen_GB
dc.typeArticleen_GB
dc.date.available2023-02-08T10:19:12Z
dc.identifier.issn2328-8930
exeter.place-of-publicationUnited States
dc.descriptionThis is the final version. Available on open access from the American Chemical Society via the DOI in this record. en_GB
dc.identifier.journalEnvironmental Science and Technology Lettersen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
dcterms.dateAccepted2022-08-11
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-08-23
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-02-08T10:13:47Z
refterms.versionFCDVoR
refterms.dateFOA2023-02-08T10:19:15Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-08-23


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2022 American Chemical Society. Open access under a CC BY-NC-ND 4.0 licence
Except where otherwise noted, this item's licence is described as © 2022 American Chemical Society. Open access under a CC BY-NC-ND 4.0 licence